Bulletin
Investor Alert

Market Pulse Archives

Aug. 21, 2019, 7:42 a.m. EDT

Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Cerecor Inc. (CERC)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Shares of Cerecor Inc. /zigman2/quotes/201368871/composite CERC +0.50% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Mannose-Phosphate Isomerase Deficiency, or MPI-CDG, a rare metabolic disorder. The FDA has granted Rockville, Md.-based Cerecor Fast Trace Designation for its CERC-802 treatment, an oral formulation of D-mannose. CERC-802 is an ultra-pure formulation of D-mannose, a naturally occurring monosaccharide that is found in animals, microorganisms, and plants, including edible fruits and herbs. "CDG patients are born with a genetic defect that hinders their ability to utilize certain monosaccharides in the production of glycoproteins," the company explained. Shares have gained 19% in 2019, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.47% has gained 16%.

/zigman2/quotes/201368871/composite
US : U.S.: Nasdaq
$ 4.02
+0.02 +0.50%
Volume: 36,464
Feb. 19, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$230.42 million
Rev. per Employee
$286,356
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,386.15
+15.86 +0.47%
Volume: 1.73B
Feb. 19, 2020 5:05p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.